

NMSIS Meeting Report NYC August 2019

Publications;

Dopamine depleters VMAT2 inhibitors: Xenazine (tetrabenazine), Ingrezza (valbenazine), Austedo (deutetrabenazine) as cause of NMS-CPN (Should inform HLC)

Frucht chapter on NMS- Third edition

Amantadine review-in press Ann Clin Psychiatry; treatment of NMS/TD.

Potential Projects;

1. Website based webinar using powerpoint presentation on TD being submitted for educational grant support from?

a. Rexulti (Otsuka)

b. Vraylor (Allergan)

c. Invega (Janssen)

d. Osmolex ER (Osmotica)

2. National VA database survey study (2004-2014) of the administration of IV dantrolene; feasibility pilot data → N=>300 IV dantrolene nationwide, (23 MH?), N=>600 hyperthermic conditions. Full protocol after IRB approval (Shah fund support with Board approval.

3. Literature review of dantrolene in NMS (Grunau et al -?Eagle)

4. RYR1 investigations of NMS and other drug-related syndromes

Misc;

Website updates ongoing- need for updated contact info

Support of office, Board and PAC for NMS-related calls and emails